U.S. Recombinant Proteins Market - Databook 2025 to 2034

The U.S. recombinant proteins market size was calculated at USD 885 million in 2024 and is predicted to attain around USD 2,874 million by 2034, expanding at a CAGR of 12.5% from 2025 to 2034.

Highlights of the U.S. Recombinant Proteins Market

• By product, the cytokines & growth factors segment held a dominant presence in the market in 2024.
• By product, the antibodies segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By application, the drug discovery & development segment accounted for a considerable share of the market in 2024.
• By application, the biopharmaceutical production segment is projected to experience the highest growth rate in the market between 2025 and 2034.
• By end-user, the pharmaceutical & biotechnology companies segment registered its dominance over the market in 2024.
• By end-user, the academic research institutes segment is set to experience the fastest rate of market growth from 2025 to 2034.

Industry Valuation and Growth Rate Projection

The U.S. recombinant protein market is rapidly expanding due to robust research, new technologies, and overall large market demand for improved healthcare. Recombinant proteins are unique proteins created in laboratories using DNA technology. In the U.S., these proteins are used to treat complex diseases such as cancer, diabetes, and rare genetic disorders. Recombinant proteins are also produced for use in vaccines and medical diagnostics.

The U.S. market has always had numerous large biotechnology and pharmaceutical companies that are working toward the discovery and innovative commercialization of new and improved injectable protein drugs. Moreover, this market is supported by the U.S. government, which they are allocating increased funding to research and development projects. Furthermore, hospitals and laboratories are taking advantage of recombinant proteins for new tests and treatments as well.

What are the Market Trends in the U.S. Recombinant Proteins Market?

• The market trends in the U.S. recombinant proteins market are promising, with a flurry of pharmaceutical companies investing in developing protein-based biologics for a variety of advanced applications.
• Increase in biologics and protein-based drugs: The U.S. has an ongoing growing demand for biologic therapies based on recombinant proteins, especially with regard to cancer and autoimmune diseases.
• Growth in personalized medicine: Recombinant proteins are being utilized in targeted approaches customized for individual patients, and this trend is increasing.
• Increase in research activities targeting rare diseases: U.S. companies are utilizing recombinant proteins to develop treatments for rare genetic disorders, which are now incurable.
• Use of AI and machine learning: U.S. biotech companies are utilizing AI to enhance protein design and structure predictions, as well as enhance drug discovery timelines.

What are the Restraints in the U.S. Recombinant Proteins Market?

• The restraints in the American recombinant proteins market have to do with the high cost of synthesis and tightening FDA approvals and need for proper testing of the product.
• High production costs: The production of recombinant proteins requires expensive equipment, expertise, and sterile conditions in a laboratory, which pushes costs.
• Complex regulatory approvals: The US FDA is very strict with protein approvals for drugs, which may cause delays in getting new products on the market.
• Risk of side effects: Recombinant proteins can cause allergic or immune responses to certain drugs, which increases uncertainty and distrust in patients.
• Intellectual property issues: Patent disputes or litigation over patent formulation can prolong drug development in the US.

What are the Opportunities in the U.S. Recombinant Proteins Market?

• There are plenty of opportunities in the market for growth including high interest in protein-based therapeutics for cancers and autoimmune conditions.
• Government funding and grants: The U.S. government is current funding biotech innovation via grants for the purpose of recombinant protein Research and Development.
• Cancer treatments demand: Cancer treatment has a significant demand for protein-based therapies that have considerable potential.
• Partnerships with major academic institutes: U.S. Biotech firms have partnerships with top-tier university institutions that develop new discoveries in recombinant protein.
• Growing Usage in Diagnostics: Recombinant proteins are now being incorporated and developed in many diagnostic kits and laboratory tests, resulting in a broader market utilization by Biotech.

Recent Developments in the U.S. Recombinant Proteins Market:

• In May 2025, Bayer announced the approval from the U.S. Food and Drug Administration (FDA) for Jivi®, a recombinant DNA-derived, extended half-life factor VIII concentrate. It is to be used in pediatric patients 7 years of age and older with hemophilia A.
• In May 2025, TurtleTree, a food tech startup, secured the first ‘no questions’ letter for precision-fermented lactoferrin from the US Food and Drug Administration. This letter validates the safety of the ingredient for food and beverages.